ClinicalTrials.gg

Program

Diphenhydramine

Also written as “Ibuprofen and Diphenhydramine Citrate”, “Diphenydramine” and “Diphenhydramine Hydrochloride Injection”.

Its studies are mostly in Sleep Initiation and Maintenance Disorders · Nasal Obstruction · Multiple Sclerosis · Depressive Disorder, Major · Urticaria, led by 9 companies.

Furthest: phase 4, since Mar 20, 200813 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson40 open or runningphase 4since Mar 20, 2008Mar 20, 2008none ahead
Dr. Reddy's Laboratories20 open or runningphase 1since Jan 20, 2010Jan 20, 2010none ahead
lumara-health-inc10 open or runningphase 2since Dec 26, 2007Dec 26, 2007none ahead
Lunan Pharmaceutical Group11 open or runningphase 3since Feb 6, 2025Feb 6, 2025none ahead
Otsuka10 open or runningphase 1since Nov 25, 2012Nov 25, 2012none ahead
Overseas Pharmaceuticals10 open or runningphase 1since Feb 6, 2023Feb 6, 2023none ahead
Pfizer10 open or runningphase 1since May 5, 2010May 5, 2010none ahead
Procter and Gamble10 open or runningphase 4since Oct 14, 2015Oct 14, 2015none ahead
TerSera Therapeutics10 open or runningphase 2since Dec 3, 2019Dec 3, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 26, 2007First study: phase 2 study in VulvodyniaNew to lumara-health-inclumara-health-inc · NCT00590590 · 105 enrolled · United States, Canada
  2. Mar 20, 2008Johnson & Johnson's first study: phase 1 study in Nasal ObstructionNew to Johnson & JohnsonJohnson & Johnson · NCT00662337 · 36 enrolled
  3. Mar 20, 2008Phase 4 study in Nasal ObstructionJohnson & Johnson · NCT00648973 · 1,021 enrolled · United States
  4. Sep 26, 2008Phase 1 study in Rhinitis, AllergicJohnson & Johnson · NCT00762749 · 36 enrolled · United States
  5. Jan 20, 2010Dr. Reddy's Laboratories's first studies: 2 phase 1 studies in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01053338, NCT01053208
  6. May 5, 2010Pfizer's first study: phase 1 study in HealthyNew to PfizerPfizer · NCT01119222 · 19 enrolled · Belgium
  7. Nov 25, 2012Otsuka's first study: phase 1 study in HealthyNew to OtsukaOtsuka · NCT01737931 · 120 enrolled · Korea, Republic of
  8. May 29, 2015Phase 1 study in Depressive Disorder, MajorJohnson & Johnson · NCT02476058 · 48 enrolled · Belgium, Germany, Netherlands
  9. Oct 14, 2015Procter and Gamble's first study: phase 4 study in Occasional SleeplessnessNew to Procter and GambleProcter and Gamble · NCT02578186 · 33 enrolled
  10. Dec 3, 2019TerSera Therapeutics's first study: phase 2 study in Oncology Patients Receiving ChemotherapyNew to TerSera TherapeuticsTerSera Therapeutics · NCT04189588 · 34 enrolled · United States
  11. Feb 6, 2023Overseas Pharmaceuticals's first study: phase 1 study in PainNew to Overseas PharmaceuticalsOverseas Pharmaceuticals · NCT05729555 · 16 enrolled · China
  12. Feb 6, 2025Lunan Pharmaceutical Group's first study: phase 3 study in Acute UrticariaNew to Lunan Pharmaceutical GroupLunan Pharmaceutical Group · NCT06819774 · 284 planned · China

TargetBeta

HRH1 →read by rule
“Histamine H1 receptor antagonist; Histamine H1 receptor antagonist”ChEMBL 37, by rule

Other programs on HRH1

ProgramCompanyFurthest phaseStudies
desloratadineruleOrganonphase 440
fexofenadineruleSanofiphase 438
bilastinerulefaes-farma-s-aphase 419

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06819774Acute Urticaria · China3RecruitingLunan Pharmaceutical GroupAug 2025284
NCT05729555Pain · China1UNKNOWNOverseas PharmaceuticalsOct 31, 202316
NCT04189588Oncology Patients Receiving Chemotherapy · United States2CompletedTerSera TherapeuticsNov 23, 202034
NCT02578186Occasional Sleeplessness4CompletedProcter and GambleDec 201433
NCT02476058Depressive Disorder, Major · Belgium, Germany, Netherlands1CompletedJohnson & JohnsonJan 4, 201648
NCT01737931Healthy · Korea, Republic of1CompletedOtsukaOct 2012120
NCT01119222Healthy · Belgium1CompletedPfizerOct 200819
NCT01053338Healthy · India1CompletedDr. Reddy's LaboratoriesApr 200840
NCT01053208Healthy · India1CompletedDr. Reddy's LaboratoriesApr 200840
NCT00762749Rhinitis, Allergic · United States1CompletedJohnson & JohnsonNov 200836
NCT00662337Nasal Obstruction1CompletedJohnson & JohnsonNov 200636
NCT00648973Nasal Obstruction · United States4CompletedJohnson & JohnsonMay 20071,021
NCT00590590Vulvodynia · United States, Canada2Completedlumara-health-incJun 2009105

How it is read

Names in the registry

  • “Diphenhydramine”, 2 entries
  • “Ibuprofen and Diphenhydramine Citrate”, 2 entries
  • “Diphenydramine”, 1 entry
  • “Diphenhydramine Hydrochloride Injection”, 1 entry
  • “Diphenhydramine 50 mg/mL”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.